New drug combo slows lung cancer growth in chinese patients
NCT ID NCT02759614
First seen Mar 18, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study tested whether adding bevacizumab to erlotinib works better than erlotinib alone for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR gene mutations. About 311 Chinese adults took part. The goal was to see if the combination could delay cancer progression longer. Results help guide treatment choices but do not offer a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.